Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 + T-DXd in HER2-low HR+ Breast Cancer
NCT06832202Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of hlx22 in breast cancer, sponsored by Henlius. Started Apr 2025; status: recruiting.
02
Drugs
hlx22
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06832202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832202.